Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis

[1]  J. Panés,et al.  Steroid‐refractory ulcerative colitis: Predictive factors of response to cyclosporine and validation in an independent cohort , 2008, Inflammatory bowel diseases.

[2]  G. Kaplan,et al.  Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. , 2008, Gastroenterology.

[3]  Faecal S 100 A 12 as a non-invasivemarker distinguishing inflammatory bowel disease from irritable bowel syndrome , 2008 .

[4]  M. Goldacre,et al.  Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies , 2007, BMJ : British Medical Journal.

[5]  A. Schoepfer,et al.  Accuracy of Four Fecal Assays in the Diagnosis of Colitis , 2007, Diseases of the colon and rectum.

[6]  D. Foell,et al.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome , 2007, Gut.

[7]  C. Lees,et al.  A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.

[8]  G. Porro,et al.  A rare cause of diuretic refractory ascites , 2005, Gut.

[9]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[10]  D. Gaya,et al.  Faecal calprotectin in the assessment of Crohn's disease activity. , 2005, QJM : monthly journal of the Association of Physicians.

[11]  M. Bottai,et al.  Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease , 2005, Gut.

[12]  S. Travis.  Predicting outcome in severe ulcerative colitis. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[13]  R. Prescott,et al.  Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second‐line medical therapy or surgery , 2004, Alimentary pharmacology & therapeutics.

[14]  A. Røseth,et al.  Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease , 2004, Scandinavian journal of gastroenterology.

[15]  M. Camilleri,et al.  Fecal Lactoferrin Is a Sensitive and Specific Marker in Identifying Intestinal Inflammation , 2003, American Journal of Gastroenterology.

[16]  F. Cremonini,et al.  Role of fecal calprotectin test in the work-up of IBS patients. , 2003, Gastroenterology.

[17]  E. Aadland,et al.  Faecal calprotectin: a marker of inflammation throughout the intestinal tract , 2002, European journal of gastroenterology & hepatology.

[18]  D. Shreeve,et al.  Faecal calprotectin: a marker of inflammation throughout the intestinal tract , 2002, European journal of gastroenterology & hepatology.

[19]  M. Fagerhol.  Calprotectin, a faecal marker of organic gastrointestinal abnormality , 2000, The Lancet.

[20]  B. Thjódleifsson,et al.  A simple method for assessing intestinal inflammation in Crohn's disease , 2000, Gut.

[21]  I. Bjarnason,et al.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.

[22]  A. Røseth,et al.  Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. , 1999, Scandinavian journal of gastroenterology.

[23]  R. Löfberg,et al.  Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis , 1998, European journal of gastroenterology & hepatology.

[24]  J. Jahnsen,et al.  Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. , 1997, Digestion.

[25]  D. Jewell,et al.  Predicting outcome in severe ulcerative colitis. , 1996, Gut.

[26]  A. Peters,et al.  Assessment of disease activity in ulcerative colitis using indium-111-labelled leukocyte faecal excretion. , 1983, Scandinavian journal of gastroenterology.

[27]  A. Peters,et al.  111Indium autologous leucocytes in inflammatory bowel disease. , 1983, Gut.

[28]  S. Truelove,et al.  FURTHER EXPERIENCE IN THE TREATMENT OF SEVERE ATTACKS OF ULCERATIVE COLITIS , 1978, The Lancet.

[29]  A. McKendrick,et al.  DENTAL CARIES AND SUGAR INTAKE , 1975, The Lancet.

[30]  A. Sood,et al.  The course and prognosis of ulcerative colitis , 1963 .

[31]  S. Truelove,et al.  The course and prognosis of ulcerative colitis , 1963, Gut.